Ongoing Stability Gaps After Raw Material Supplier Changes

Troubleshooting Ongoing Stability Gaps Following Changes in Raw Material Suppliers Changes in raw material suppliers can introduce significant risks to pharmaceutical manufacturing stability, potentially leading to ongoing stability program gaps.…

Why Regulators Reject Weak ICH Q1D Justifications

Understanding and Resolving Issues with ICH Q1D Justifications in Bracketing and Matrixing In today’s complex pharmaceutical landscape, compliance with regulatory frameworks like ICH Q1D is critical for ensuring the validity…

Ongoing Stability Pull Window Deviations and Corrective Actions

Managing Deviations in Ongoing Stability Programs: A Step-by-Step Approach Pharmaceutical manufacturers often encounter challenges related to ongoing stability program gaps, impacting regulatory compliance and product integrity. This piece will empower…

How to Create a Defensible Matrixing Pull Schedule

Strategies to Address Bracketing and Matrixing Misuse in Stability Studies The pharmaceutical industry faces significant challenges when implementing stability studies, particularly concerning bracketing and matrixing methodologies. Frequent errors in creating…

Ongoing Stability Program Gaps in Biologics and Vaccines

Addressing Gaps in Ongoing Stability Programs for Biologics and Vaccines In the ever-evolving landscape of pharmaceutical development, maintaining the integrity of biologics and vaccines is crucial. However, many organizations encounter…